The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUBG.L Regulatory News (UBG)

  • There is currently no data for UBG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Operating Review - Replacement

17 Jan 2023 08:30

RNS Number : 9713M
Unbound Group PLC
17 January 2023
 

The following amendment has been made to the 'Trading Update and Operating Review' announcement released on 17 January 2023 at 07:00 under RNS Number 8967M:

 

Deleting the reference to "and adjusted pre-tax profit of £1.0m respectively" in the footnote at the end of the announcement.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

Unbound Group plc

('the Group')

 

Trading Update and Operating Review

 

Unbound Group plc today provides an update on its trading performance in the year to 5th February 2023 (FY23) and announces significant initiatives focused on optimising the efficiency and growth of the Group.

 

Trading Update

 

Despite a cautionary outlook at the Group's interim results, trading conditions in the second half of the financial year have been more challenging. Several external factors, including the extended period of hot weather, the impact of Royal Mail industrial action and broader economic conditions significantly impacted sales of our Autumn/Winter range in the final five months of the year.

 

Following a strong start to the year, revenue growth has slowed with a poor Q3 and November performance and a small return to growth in December and in January to date. As a result, full year revenue is now expected to be £53-£54m, 3-4% growth on the prior year. Gross margins have been broadly in line with expectation. Given this, we now expect to incur a pre-IFRS16 adjusted EBITDA loss of £0.75-£1.25m and adjusted pre-tax loss of £4.25-£4.75m (both pre-exceptional and after non-recurring costs of c.£1m) in FY23, below current market expectations*.

 

Net banking debt as at 31 December 2022 was £8.8m after investing £1.5m in pre-payment of spring range extension stock. This provides current funding headroom of at least £1.3m, which the Board expects will increase in Q1 of the financial year ending 4th February 2024 ("FY24") as the incremental inventory investment in working capital reverses. Having developed the Unbound platform in the current financial year, capital expenditure in FY24 will be substantially lower than FY23.

 

Despite the short-term challenges experienced, the Group is well positioned for an enhanced Spring / Summer product portfolio launch supported by well-balanced inventory levels. Following the success of recent sourcing trials, we will be introducing incremental new product styles, including a new range of athleisure products.

 

The Unbound Group currently has 11 partner brands that have gone live over the past five months. We anticipate signing further partnerships in 2023 and still see significant scope for growth and complementary brand diversification over the medium term. However, given the current consumer backdrop the partnership model has had a slow start to trading, as management has focused attention on its core Hotter brand.

 

 

 

 

 

Focus on efficiency and growth

 

As highlighted previously, to optimise the Group's trading performance in the current challenging economic and market conditions, focus will remain on managing costs, protecting margins and cashflow, ensuring that appropriate levels of working capital are maintained and managing capital investment tightly. In line with strategy, annualised cost savings of approximately £2.3m have already been identified within the Group's existing operating model, with £1.3m being realised across the final quarter of the current financial year and into the first quarter of the next financial year. A further £1m will be realised across Q2 and Q3 of FY24.

 

The cost reduction activity outlined above is intended to underpin a return to pre-IFRS16 EBITDA profitability during the next financial year. Furthermore, the Board has accelerated its planned review of the operating structure of the Group. This is focused on streamlining activities and simplifying processes in order to drive growth of revenue and profits.

 

The review will cover areas including:

 

· The most appropriate structure and strategy for the future of its US business, which contributes 11% of revenues

· Broadening the product range to ensure that styles remain relevant and attractive to the consumer but with reduced SKUs and resultant business complexity

· Further development of the Unbound Group trading platform, which now has 11 partner brands selected for relevance to our over 55-year-old target customer demographic.

 

Further detail on the key outputs from the Board's growth and efficiency review will be provided alongside the Group's FY23 annual results, expected to be published in May.

 

Ian Watson, Chief Executive, commented:

 

"Since our strong start to the year, trading in the second half has been disappointing, with weakened demand from the current economic slowdown and a number of external factors. However, we are pleased that margin discipline was maintained.

 

Our core brand Hotter retains a highly loyal and engaged customer base. We will focus on a broader product range, driven by our insight into our customer's needs, attitudes and behaviours. In reaction to the challenging trading environment, our strategic focus is centred around growth and simplification. The Group will also generate significant annualised cost savings which will be fully implemented by the end of October 2023.

 

As we continue to navigate our way through the current challenging consumer backdrop, I remain confident in the long-term future of Hotter and the wider Unbound platform as we build strategic partnerships with brands who want to partner with us to target our Group's key demographic."

 

 

* Current consensus market expectations for the year ending 5th February 2023 are for revenue of £57.7m, pre-IFRS16 adjusted EBITDA of £2.3m and an adjusted pre-tax loss of £1.2m.

 

Enquiries

 

Unbound Group plc

Ian Watson, CEO

c/o Alma PR

Gavin Manson, CFO 

 

Singer Capital Markets

Peter Steel / Tom Salvesen / Alaina Wong

 

+44 (0) 20 7496 3000

 

 

Alma PR Limited (Financial PR)

 

+44 (0) 20 3405 0205

Josh Royston / Sam Modlin/ Hannah Campbell

unbound@almapr.co.uk

 

 

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGIGDBSDBDGXR
Date   Source Headline
25th Apr 20239:33 amRNSForm 8.5 (EPT/RI)
24th Apr 202310:29 amRNSForm 8.5 (EPT/RI)
21st Apr 202311:57 amRNSForm 8.3 - Unbound Group PLC
21st Apr 202311:15 amRNSForm 8.5 (EPT/RI)
20th Apr 202312:00 pmRNSForm 8.5 (EPT/RI) - Unbound Group Plc
20th Apr 202310:04 amRNSForm 8.5 (EPT/RI)
20th Apr 20239:33 amRNSForm 8.3 - Unbound Group plc
19th Apr 202311:05 amRNSForm 8.5 (EPT/RI)
18th Apr 202312:00 pmRNSForm 8.5 (EPT/RI) - Unbound Group Plc
18th Apr 202311:55 amRNSForm 8.5 (EPT/RI)
18th Apr 20239:24 amRNSForm 8.3 - Unbound Group PLC
17th Apr 20235:05 pmRNSForm 8.3 - Unbound Group PLC
17th Apr 202312:00 pmRNSForm 8.5 (EPT/RI) - Unbound Group Plc
17th Apr 202311:46 amRNSForm 8.5 (EPT/RI)
14th Apr 202312:00 pmRNSForm 8.5 (EPT/RI) - Unbound Group Plc
14th Apr 202311:56 amRNSForm 8.5 (EPT/RI)
13th Apr 202312:00 pmRNSForm 8.5 (EPT/RI) - Unbound Group Plc
13th Apr 20239:29 amRNSForm 8.5 (EPT/RI)
12th Apr 20231:09 pmRNSPossible Investment from Marwyn
12th Apr 202312:00 pmRNSForm 8.5 (EPT/RI) - Unbound Group Plc
11th Apr 20231:27 pmRNSForm 8.3 - Unbound Group Plc
6th Apr 20235:47 pmRNSForm 8.3 - Unbound Group plc
6th Apr 20235:44 pmRNSForm 8.3 - Unbound Group plc
6th Apr 20231:52 pmRNSForm 8 (OPD) - Unbound Group plc
6th Apr 202312:00 pmRNSForm 8.5 (EPT/RI) - Unbound Group Plc
5th Apr 20232:20 pmRNSForm 8.3 - Unbound Group plc
5th Apr 202310:48 amRNSForm 8.5 (EPT/RI)
4th Apr 202311:14 amRNSForm 8.5 (EPT/RI) - Unbound Group PLC
3rd Apr 20233:52 pmRNSForm 8.3 - Unbound Group plc
3rd Apr 20232:18 pmRNSForm 8.3 - Unbound Group Plc
3rd Apr 202312:00 pmRNSForm 8.5 (EPT/RI) - Unbound Group Plc
3rd Apr 20238:57 amRNSForm 8.5 (EPT/RI)
31st Mar 202312:00 pmRNSForm 8.5 (EPT/RI) - Unbound Group Plc
31st Mar 202310:53 amRNSForm 8.5 (EPT/RI)
30th Mar 20232:54 pmRNSForm 8.3 - Unbound Group PLC
30th Mar 202312:00 pmRNSForm 8.5 (EPT/RI) - Unbound Group Plc
30th Mar 202310:40 amRNSForm 8.5 (EPT/RI)
29th Mar 20233:07 pmRNSForm 8.3 - Unbound Group Plc
29th Mar 202312:00 pmRNSForm 8.5 (EPT/RI) - Unbound Group Plc
29th Mar 202311:37 amRNSForm 8.5 (EPT/RI)
29th Mar 20238:45 amBUSForm 8.3 - Unbound Group plc
28th Mar 20235:11 pmRNSForm 8.3 - Unbound Group plc
28th Mar 20231:48 pmRNSForm 8.3 - UNBOUND GROUP PLC
28th Mar 20239:05 amRNSSecond Price Monitoring Extn
28th Mar 20239:00 amRNSPrice Monitoring Extension
28th Mar 20237:00 amRNSAnnouncement regarding Possible Offer
13th Feb 202312:47 pmRNSHolding(s) in Company
7th Feb 202311:05 amRNSSecond Price Monitoring Extn
7th Feb 202311:00 amRNSPrice Monitoring Extension
7th Feb 20237:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.